Skip to content

Yoga for Pain and Opioid Dependence

Yoga for Pain and Opioid Dependence

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01590251
Acronym
Yoga
Enrollment
8
Registered
2012-05-02
Start date
2012-04-30
Completion date
2014-11-30
Last updated
2015-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Opioid Addiction

Keywords

Pain, Addiction, Buprenorphine, Counseling, Methadone, Yoga

Brief summary

This study is designed to develop an effective adjunctive treatment using yoga for chronic pain and opioid dependence.

Detailed description

This study aims to develop an adjunctive novel treatment intervention using yoga in opioid agonist maintained patients to effectively treat the co-occurring disorders of non-malignant chronic pain and opioid dependence (POD). Specific Aims: 1\) To conduct a pre-pilot phase with 8 patients with POD receiving opioid agonist maintenance treatment.

Interventions

OTHERYoga

Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.

One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * Prescription opioid addiction or heroin addiction * Moderate to severe chronic pain, * Understands English

Exclusion criteria

* Current suicide or homicide risk * Life threatening or unstable medical condition * Medical or psychiatric condition that is judged to be of clinical concern by the PI or admitting clinician * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pain reduction8 weeksPain reduction will be measured by patient self-report using standard pain rating scales.
Reduce illicit opioid use8 weeksReduced illicit opioid use will be measured by patient self-report and urinalysis testing.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026